Version 1
: Received: 20 April 2023 / Approved: 20 April 2023 / Online: 20 April 2023 (07:52:10 CEST)
How to cite:
Komura, Y.; Kimura, S.; Katagiri, T.; Hirasawa, Y.; Hirayama, M.; Okuda, T.; Muranishi, H.; Homma, K. Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer. Preprints2023, 2023040625. https://doi.org/10.20944/preprints202304.0625.v1
Komura, Y.; Kimura, S.; Katagiri, T.; Hirasawa, Y.; Hirayama, M.; Okuda, T.; Muranishi, H.; Homma, K. Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer. Preprints 2023, 2023040625. https://doi.org/10.20944/preprints202304.0625.v1
Komura, Y.; Kimura, S.; Katagiri, T.; Hirasawa, Y.; Hirayama, M.; Okuda, T.; Muranishi, H.; Homma, K. Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer. Preprints2023, 2023040625. https://doi.org/10.20944/preprints202304.0625.v1
APA Style
Komura, Y., Kimura, S., Katagiri, T., Hirasawa, Y., Hirayama, M., Okuda, T., Muranishi, H., & Homma, K. (2023). Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer. Preprints. https://doi.org/10.20944/preprints202304.0625.v1
Chicago/Turabian Style
Komura, Y., Hiromi Muranishi and Koichiro Homma. 2023 "Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer" Preprints. https://doi.org/10.20944/preprints202304.0625.v1
Abstract
Cisplatin (CDDP) is a platinum-based drug effective against various cancers, including lung, bladder, prostate, ovarian, esophageal, stomach, and cervical cancer and malignant lymphoma. It plays a central role as the first choice in current anticancer therapy. However, CDDP causes serious side effects, such as neurological disorders, myelosuppression, and renal damage, because it is a small molecule indiscriminately distributed in normal tissues. Therefore, it is very important to prevent or attenuate CDDP toxicity. We hypothesized that liposomalization of CDDP could alleviate serious side effects. Therefore, this study aimed to evaluate the safety and efficacy of CDDP liposomes. A patient with multiple recurrent liver metastases from metastatic nasal carcinoma was administered CDDP liposomes with consent. Magnetic resonance imaging showed that the patient remained stable-diseased; however, no apparent side effects were observed, and blood draw data showed no worsening of renal function. Patients undergoing partial pancreatectomy and jejunoileal biliary anastomosis for biliary tract cancer who consented to receive CDDP liposomes demonstrated a partial response on angiographic computed tomography; however, they showed slight fatigue. To our knowledge, the present study is the first in Japan to suggest that liposomalization of CDDP may have anticancer effects while alleviating renal damage and bone marrow suppression.
Keywords
adverse drug reaction; cisplatin liposomes; circulating tumor cells; enhanced permeability and retention effect; nephrotoxicity; pulmonary metastasis of pancreatic cancer; quality of life; recurrent liver metastases from primary nasal cancer
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
